Integrating bevacizumab and radiation treatment of brain metastasis: Is there sense and sensibility in this approach?

Emil Lou, Paul W. Sperduto

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The incidence of brain metastasis has increased over the past decade. Standard treatment options for brain metastases include whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS) and surgery for patients with operable lesions and either mass effect or need for histologic confirmation of the diagnosis. Patients are living longer due to improvements in systemic therapeutic approaches, included targeted therapies such as inhibition of vascular endothelial growth factor (VEGF) using the monoclonal antibody bevacizumab (Bev). A recent phase I trial (REBECA) investigated adding Bev to whole-brain radiation for patients with brain metastasis from solid tumors. In this Perspectives article, we discuss the results of the REBECA trial in context of advancements in radiation and medical oncology in the era of targeted therapies, and discuss pertinent questions of interest in this field.

Original languageEnglish (US)
Article number36
JournalAnnals of Translational Medicine
Volume4
Issue number2
DOIs
StatePublished - Jan 2016

Keywords

  • Angiogenesis
  • Bevacizumab (Bev)
  • Brain metastasis
  • Vascular endothelial growth factor (VEGF)
  • Whole-brain radiation

Fingerprint Dive into the research topics of 'Integrating bevacizumab and radiation treatment of brain metastasis: Is there sense and sensibility in this approach?'. Together they form a unique fingerprint.

Cite this